Natalie K. Horvat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalie K. Horvat has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Gregory B. Lesinski
Emory University
63 shared publications - Chrystal M. Paulos
Winship Cancer Institute, Emory University
45 shared publications - Emily Greene
Department of Hematology & Medical Oncology, Emory University, Atlanta, USA
43 shared publications - Alyssa M. Krasinskas
Department of Pathology, Emory University, Atlanta, USA
42 shared publications - Bassel F. El-Rayes
Division of Hematology and Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
42 shared publications - Cameron J. Herting
Emory University 1 Department of Hematology and Medical Oncology Atlanta, Georgia
42 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S5. In vivo characterization of miR-29 modulated cells.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S5. In vivo characterization of miR-29 modulated cells.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S1. Primer and guide RNA sequences used in enclosed studies.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S1. Primer and guide RNA sequences used in enclosed studies.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S4. Modulating miR-29a/b1 expression controls ATX, other miR-29 target genes, and tumor cell growth in 2-D and 3-D cultures.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S4. Modulating miR-29a/b1 expression controls ATX, other miR-29 target genes, and tumor cell growth in 2-D and 3-D cultures.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S6. Effects on immune cell populations as a function of miR-29.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S6. Effects on immune cell populations as a function of miR-29.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S7. Correlation of transcripts with miR-29a in lung adenocarcinoma tumors from TCGA.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S7. Correlation of transcripts with miR-29a in lung adenocarcinoma tumors from TCGA.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S7. Analyses of the miR-29 family in LUAD patients.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S7. Analyses of the miR-29 family in LUAD patients.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Immune checkpoint inhibitors (ICI), including those that block PD-1/PD-L1, have revolutionized therapy for patients with non–small cell lung cancer. However, most patients demonstrate no clinical benefit or acquire resistance, even when tumors express PD-L1. This highlights the critical need to dissect tumor survival dependencies to overcome resistance. Using our Kras/p53-driven lung cancer models that demonstrate acquired or intrinsic resistance to ICIs, we performed single-cell RNA sequencing (scRNA-seq) and focused on predicted upstream regulators of differentially expressed genes in the malignant cell cluster of resistant tumors. We found that the micro-RNA miR-29 was downregulated in tumors with anti–PD-1 resistance and that this was associated with significant upregulation of a multitude of miR-29 targets. Furthermore, we found that expression of Enpp2/ATX, a gene encoding an immunosuppressive molecule, was modulated due to miR-29 loss. Reexpression of miR-29 in anti–PD-1–resistant models reduced ATX expression in tumor cells, diminished the fibrotic microenvironment, and increased CD8+ T-cell infiltration. These alterations promoted response to ICIs in an anti–PD-1–resistant model by rewiring the tumor-immune microenvironment, specifically through increased CD8+ T-cell infiltration, reduction of suppressive Ly6C+ monocytes, and a concomitant increase in proinflammatory macrophages. Additional analysis of publicly available RNA-seq data revealed that tumors from patients with lung adenocarcinoma with high miR-29 had increased CD8A and decreased CD14 expression and broad enrichment in immunoregulatory pathways. Together, these data provide evidence that the miR-29 family regulates the tumor microenvironment, including antitumor immune-related pathways in lung cancer, through control of ATX among other target genes, with implications for ICI response.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Immune checkpoint inhibitors (ICI), including those that block PD-1/PD-L1, have revolutionized therapy for patients with non–small cell lung cancer. However, most patients demonstrate no clinical benefit or acquire resistance, even when tumors express PD-L1. This highlights the critical need to dissect tumor survival dependencies to overcome resistance. Using our Kras/p53-driven lung cancer models that demonstrate acquired or intrinsic resistance to ICIs, we performed single-cell RNA sequencing (scRNA-seq) and focused on predicted upstream regulators of differentially expressed genes in the malignant cell cluster of resistant tumors. We found that the micro-RNA miR-29 was downregulated in tumors with anti–PD-1 resistance and that this was associated with significant upregulation of a multitude of miR-29 targets. Furthermore, we found that expression of Enpp2/ATX, a gene encoding an immunosuppressive molecule, was modulated due to miR-29 loss. Reexpression of miR-29 in anti–PD-1–resistant models reduced ATX expression in tumor cells, diminished the fibrotic microenvironment, and increased CD8+ T-cell infiltration. These alterations promoted response to ICIs in an anti–PD-1–resistant model by rewiring the tumor-immune microenvironment, specifically through increased CD8+ T-cell infiltration, reduction of suppressive Ly6C+ monocytes, and a concomitant increase in proinflammatory macrophages. Additional analysis of publicly available RNA-seq data revealed that tumors from patients with lung adenocarcinoma with high miR-29 had increased CD8A and decreased CD14 expression and broad enrichment in immunoregulatory pathways. Together, these data provide evidence that the miR-29 family regulates the tumor microenvironment, including antitumor immune-related pathways in lung cancer, through control of ATX among other target genes, with implications for ICI response.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S1. scRNA-seq quality control and cluster analysis.
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S1. scRNA-seq quality control and cluster analysis.
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S6. Quantitation of the chemokine/cytokine array completed on PD1R-control and miR-29 tumors
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Table S6. Quantitation of the chemokine/cytokine array completed on PD1R-control and miR-29 tumors
- Open Access
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S2. Negative correlation between ATX and miR-29a/b in TCGA lung adenocarcinoma samples and human lung cancer cell lines
- 2 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer
Figure S2. Negative correlation between ATX and miR-29a/b in TCGA lung adenocarcinoma samples and human lung cancer cell lines